Summit Therapeutics Inc. (SMMT)
| Market Cap | 16.50B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.08B |
| Shares Out | 776.08M |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,950,148 |
| Open | 22.02 |
| Previous Close | 22.12 |
| Day's Range | 21.25 - 22.40 |
| 52-Week Range | 13.83 - 30.98 |
| Beta | -1.37 |
| Analysts | Buy |
| Price Target | 32.93 (+54.89%) |
| Earnings Date | May 12, 2026 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $32.93, which is an increase of 54.89% from the latest price.
News
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst
Ivonescimab is a PD-1xVEGF bispecific antibody under development for cancer, primarily for lung cancer.
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecifi...
Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Ivonescimab has shown strong efficacy and tolerability in multiple phase 3 studies, outperforming PD-1 inhibitors in both monotherapy and combination settings. Key regulatory milestones are set for 2026, with broad expansion plans across major solid tumor indications.
Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted the global expansion of ivonescimab through multiple late-stage studies, regulatory progress with a 2026 PDUFA date, and strong efficacy and safety data across regions. Upcoming milestones include interim and final analyses in lung and colorectal cancer, with further studies planned.
Summit Therapeutics to Present at Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during Marc...
Summit Therapeutics Earnings Call Transcript: Q4 2025
Ivonescimab continues to show strong clinical and commercial momentum, with positive phase III data, a robust global pipeline, and a potential US approval in late 2026. Financial discipline is evident with a strong cash position and controlled expenses, supporting ongoing R&D and commercial readiness.
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational prog...
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2025 financial resu...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of...
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summ...
Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Ivonescimab has established a leadership position in the PD-1/VEGF space with four positive phase III trials, regulatory submissions, and a robust global pipeline. Strategic collaborations, strong financials, and upcoming data readouts position 2026 as a pivotal year for expansion and commercialization.
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab...
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to the U.S. Foo...
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44th Annual J.P. Morgan Heal...
Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Ivonescimab has demonstrated robust efficacy and safety across multiple global phase 3 trials, with consistent results in both Eastern and Western populations. The company is expanding into new indications and novel combinations, maintaining a strong competitive position and prioritizing patient access and strategic independence.
Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025
The session highlighted rapid progress in oncology, with four positive phase III trials for ivonescimab, strong global data consistency, and accelerated regulatory timelines. The team remains confident in its independent strategy, financial strength, and ability to outpace competitors.
Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Ivonescimab, a bispecific PD-1/VEGF antibody, has shown strong efficacy and safety in multiple phase III trials, with consistent results across global populations. Key milestones include a BLA filing this quarter, pivotal data readouts in 2026, and expansion into colorectal cancer.
Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025
Ivonesimab, a PD-1/VEGF bispecific antibody, has shown consistent efficacy and safety across multiple phase 3 trials, with strong translatability between Chinese and Western populations. Rapid enrollment and protocol amendments in global trials are accelerating timelines, while expansion into new indications and combination strategies position the asset competitively in a growing market.
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results f...
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and spo...
Summit Therapeutics Raises $500 Million in Private Placement
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institut...
What's Going On With Summit Therapeutics Stock On Monday?
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results.
Summit Therapeutics Earnings Call Transcript: Q3 2025
Ivonescimab plus chemotherapy showed significant PFS benefit in phase III HARMONi-6 for advanced squamous NSCLC, supporting a planned BLA submission in Q4 2025. Financially, Q3 2025 ended with $238.56M in cash and lower GAAP expenses. The clinical program expanded to 14 phase III trials across multiple tumors.
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the ...
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsore...